Market News AIOpen the app

Jaguar Health shared its third-quarter results, showing less debt and changes in revenue from Future Pak.

ResultsRead the original at SEC EDGAR
Neutral

Jaguar's total revenue fell 24%, but its net loss narrowed 39.6% and it cut debt by $10.1 million. These mixed results do not clearly change its business outlook.

JAGX · Jaguar Health, Inc.

AI read · Neutral

The AI's read

The sales decline came as Jaguar shifted U.S. marketing of Mytesi and Canalevia-CA1 to Future Pak. Jaguar still makes those products, but U.S. sales go to Future Pak. Losses narrowed, and Jaguar also reduced its debt. It plans to seek approval for its rare-disease treatment in mid-2027, but that step has not happened yet. These facts point in different directions, so the report does not show a clear change in the company's outlook.

Get alerts for JAGX

Follow Jaguar Health, Inc. (JAGX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for JAGX
Free on the App Store and Google Play, or on the web.